GlaxoSmithKline Pakistan (KAR:GLAXO) Land And Improvements: ₨ Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:GLAXO GlaxoSmithKline Pakistan Ltd KAR:GLAXO
93 GF Score
Price ₨320.99
GF Value ₨348.54
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is GlaxoSmithKline Pakistan Land And Improvements?

GlaxoSmithKline Pakistan KAR:GLAXO +2.03% 93 Land And Improvements is ₨ Mil as of Jun. 2026. GuruFocus rates KAR:GLAXO with a GF Score™ of 93/100 and a GF Value™ of ₨348.54 (Fairly Valued). The stock has 2 warning signs investors should review.

GlaxoSmithKline Pakistan's land and improvements for the quarter that ended in Jun. 2026 was ₨ Mil.

GlaxoSmithKline Pakistan's annual land and improvements stayed the same from Dec. 2023 (₨316 Mil) to Dec. 2024 (₨316 Mil) and stayed the same from Dec. 2024 (₨316 Mil) to Dec. 2025 (₨316 Mil).

GlaxoSmithKline Pakistan Land And Improvements Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pakistan's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pakistan Land And Improvements Chart

GlaxoSmithKline Pakistan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Land And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 316.41 316.41 316.41 316.41

GlaxoSmithKline Pakistan Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
KAR:GLAXO
93GF Score
GlaxoSmithKline Pakistan Ltd KAR:GLAXO
Land And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pakistan Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Frequently Asked Questions Learn more about Land And Improvements →
What does a Land And Improvements of ₨ Mil mean?
GlaxoSmithKline Pakistan (KAR:GLAXO) has a Land And Improvements of ₨ Mil as of Jun. 2026. Land and improvements records the total value of a company's land and improvements to it. View historical data on GlaxoSmithKline Pakistan and its competitors.
Is GlaxoSmithKline Pakistan's Land And Improvements too high?
GlaxoSmithKline Pakistan's current Land And Improvements is ₨ Mil. Overall, GlaxoSmithKline Pakistan has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pakistan's Land And Improvements compare to ZTS and UTHR?
GlaxoSmithKline Pakistan's Land And Improvements of ₨ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Land And Improvements for a Drug Manufacturers company?
A good Land And Improvements depends on the Drug Manufacturers industry context. However, Land And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Land And Improvements mean?
A high Land And Improvements can signal that a stock is expensive relative to its fundamentals. Land and improvements records the total value of a company's land and improvements to it. View historical data on GlaxoSmithKline Pakistan and its competitors. GlaxoSmithKline Pakistan's current Land And Improvements is ₨ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pakistan stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pakistan (KAR:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₨348.54, compared to a current price of ₨320.99 — trading 7.9% below its estimated fair value. The current Land And Improvements is ₨ Mil. GlaxoSmithKline Pakistan's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Land And Improvements calculated?
Land And Improvements is calculated from a company's financial statements. For GlaxoSmithKline Pakistan (KAR:GLAXO), the current Land And Improvements is ₨ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pakistan (KAR:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pakistan stock appears to be undervalued. The current stock price of ₨320.99 is trading 7.9% below its estimated GF Value™ of ₨348.54. GuruFocus considers GlaxoSmithKline Pakistan to be Fairly Valued.

Key valuation signals for KAR:GLAXO:

  • Land And Improvements: ₨ Mil
  • GF Value™: ₨348.54 vs. price of ₨320.99 (7.9% below fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the KAR:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pakistan Business Description

Address 35, Dockyard Road, West Wharf, Karachi, PAK, 74000
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company operates in single segment which is the Pharmaceuticals segment.
93GF Score

Get the complete analysis for KAR:GLAXO

Land And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨320.99
Price
₨348.54
GF Value